Industry News
Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma
Sep 30, 2014
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with... Read More
Melanoma drug combo improves patient survival rate, decreases risk of harsh side effect
Sep 30, 2014
A UCLA researcher at the Jonsson Comprehensive Cancer Center helped pioneer a new therapy that combines the drug Zelboraf® with an experimental drug cobimetinib, allowing metastatic melanoma... Read More
AZD9291 shows durable clinical response in patients with advanced EGFR mutation positive non-small cell lung cancer
Sep 30, 2014
Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8. Read More
Promising results shown with targeted approaches in subsets of non-small cell lung cancer
Sep 30, 2014
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according... Read More
Studies report new findings on treatment options for mesothelioma
Sep 30, 2014
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to... Read More
IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
Sep 30, 2014
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in... Read More
Adding cediranib to chemotherapy improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows
Sep 30, 2014
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage... Read More
Scan may identify lung cancer patients who will benefit from folate-targeted drug
Sep 30, 2014
Study using thymidylate synthase as a predictive and prospective biomarker; Report on a trial with a drug that targets the folate receptorMeasuring the expression levels of an enzyme involved in... Read More
Crizotinib treatment led to significant tumor shrinkage in 72 percent of ROS1-positive lung cancer patients
Sep 30, 2014
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. Read More
Zytiga® (abiraterone acetate) survival data in chemotherapy-naïve men with metastatic castration resistant prostate cancer (mCRPC) revealed
Sep 30, 2014
Data from the final analysis of the Phase 3 study COU-AA-302 have shown that Zytiga® (abiraterone acetate) plus low dose prednisolone significantly prolongs overall survival (OS) with a median... Read More
Previous Page Next Page